Hogan Lovells advises Valneva in its €50 million fundraising

Hogan Lovells has advised Valneva in its €50 million fundraising of gross proceeds in a private placement of its ordinary shares.

The transaction led by blue-chip US healthcare investors and supported by the Company’s existing major shareholders, was heavily oversubscribed.

Valneva is a commercial stage biotech company focused on developing innovative lifesaving vaccines. This investment supports its capital access strategy and future growth, including the acceleration of its key development programs.

Valneva is listed on Euronext-Paris and the Vienna stock exchange.

The international Hogan Lovells team advising Valneva was made up of Jean-Marc Franceschi (partner), Arnaud Deparday (senior associate) and Sarah Naidji (associate) in Paris; Richard Parrino (partner) in Washington. 


Share Back To Listing

Loading data